ASCO Plenary Presentation for ANZSA sponsored rEECUR clinical trial
Research conducted by ANZSA featured in the rEECUR plenary presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past June.
The ASCO annual meeting is by far one of the largest cancer-based research meetings in the world. On average, the meeting has over 30,000 attendees and nearly 6,000 abstracts are submitted annually, yet only five are select for plenary presentations. ANZSA partnered with other cancer associations around the world to produce the presentation — with board member Prof. Marianne Phillips working as a co-author on the project.
This is a major achievement for the sarcoma community and for ANZSA, on an international stage. The rEECUR study is a ground-breaking study for Ewing Sarcoma patients that will continue to recruit to new arms of investigations. ANZSA with our international partners and our local collaborators ANZCHOG (ANZ Children’s & Haematology Oncology Group) are proud to be able to offer this study for our Australian and New Zealand patients.
The presentation focused on the research into the rEECUR trial that ANZSA is participating in amongst other cancer research organisations around the world. rEECUR is an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.
In other rEECUR news, the GPA Andrew Ursini Charitable Fund recently donated $40,000 to ANZSA to continue to fund the rEECUR project for the next financial year. This funding will help support patients who qualify for the Canteen funding age range (15 – 25).